252
Participants
Start Date
August 31, 2015
Primary Completion Date
November 3, 2017
Study Completion Date
September 30, 2018
VB-111 + bevacizumab
"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months~Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
Bevacizumab
Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
University of Louisville, Louisville
Metro-MN Community Oncology Research Consortium, Minneapolis
Washington University School of Medicine, St Louis
Texas Oncology-Austin Midtown, Austin
University of Alabama, Birmingham
Highlands Oncology Group, Rogers
University of California Irvine Medical Center, Irvine
University of California Los Angeles, Los Angeles
The Center for Cancer Prevention and Treatment, Orangevale
Kaiser Permanente - Redwood City Medical Center, Redwood City
University of California, San Diego
University of California San Francisco, San Francisco
Stanford University, Stanford
Colorado Neurological Institute, Denver
The George Washington University Medical Faculty Associates, Washington D.C.
University of Florida Preston A. Wells, Jr. Center for Brain Tumor Therapy, Gainesville
Orlando Health, Orlando
Piedmont Physicians Neuro-Oncology, Atlanta
Northwestern University, Chicago
The University of Chicago, Chicago
University of Kansas Medical Center, Kansas City
University of Kentucky, Lexington
Louisiana State University Health Science Center, Shreveport
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
University of Michigan Comprehensive Cancer Center, Ann Arbor
Henry Ford Health System, Detroit
Dartmouth Hitchcock Medical Center, Lebanon
Dent Neurosciences Research Center, Amherst
North Shore University Hospital, Lake Success
Columbia University Medical Center, New York
Derald H. Ruttenberg Treatment Center, New York
University of Rochester Medical Center, Rochester
Stony Brook University, Neurology Associates of Stony Brook, Stony Brook
SUNY Upstate Medical University, Syracuse
University of North Carolina at Chapel Hill, Chapel Hill
Wake Forest Baptist Medical Center, Winston-Salem
Penn State Milton S Hershey Medical Center, Hershey
University of Pittsburgh Medical Center, Pittsburgh
Baylor Health Neuro-Oncology Associates, Dallas
University of Texas Southwestern Medical Center, Dallas
: University of Texas, HSC, Houston
MD Anderson, Houston
UTHSCSA, San Antonio
Huntsman Cancer Institute at The University of Utah, Salt Lake City
University of Virginia, Charlottesville
Swedish Medical Center, Seattle
University of Wisconsin, Madison
Tom Baker Cancer Centre, Calgary
London Health Sciences Centre, London
Ottawa Hospital, Ottawa
Sunnybrook Health Science Centre, Toronto
Rambam Medical Center, Haifa
Hadassah Medical Center, Jerusalem
Rabin Medical Center, Petach Tikvah
Chaim Sheba Medical Center, Ramat Gan
Tel Aviv Sourasky Medical Center, Tel Aviv
Vascular Biogenics Ltd. operating as VBL Therapeutics
INDUSTRY